1. Nervonic acid protects against oligodendrocytes injury following chronic cerebral hypoperfusion in mice.
- Author
-
Zheng W, Xu G, Lue Z, Zhou X, Wang N, Ma Y, Yuan W, Yu L, Zhu D, and Zhang X
- Subjects
- Animals, Mice, Male, Brain Ischemia drug therapy, Brain Ischemia pathology, Hippocampus drug effects, Hippocampus pathology, Hippocampus metabolism, Disease Models, Animal, Cognition drug effects, Corpus Callosum drug effects, Corpus Callosum pathology, Chronic Disease, Cells, Cultured, Oligodendroglia drug effects, Oligodendroglia metabolism, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use, Apoptosis drug effects, Mice, Inbred C57BL
- Abstract
Chronic cerebral hypoperfusion (CCH) has been acknowledged as a potential contributor to cognitive dysfunction and brain injury, causing progressive demyelination of white matter, oligodendrocytes apoptosis and microglia activation. Nervonic acid (NA), a naturally occurring fatty acid with various pharmacological effects, has been found to alleviate neurodegeneration. Nonetheless, evidence is still lacking on whether NA can protect against neurological dysfunction resulting from CCH. To induce CCH in mice, we employed the right unilateral common carotid artery occlusion (rUCCAO) method, followed by oral administration of NA daily for 28 days after the onset of hypoperfusion. We found that NA ameliorated cognitive function, as evidenced by improved performance of NA-treated mice in both novel object recognition test and Morris water maze test. Moreover, NA mitigated demyelination and loss of oligodendrocytes in the corpus callosum and hippocampus of rUCCAO-treated mice, and prevented oligodendrocyte apoptosis. Furthermore, NA protected primary cultured murine oligodendrocytes against oxygen-glucose deprivation (OGD)-induced cell death in a concentration-dependent manner. These findings indicated that NA promotes oligodendrocyte maturation both in vivo and in vitro. Our findings suggest that NA offers protective effects against cerebral hypoperfusion, highlighting its potential as a promising treatment for CCH and related neurological disorders., Competing Interests: Declaration of competing interest The authors declare no competing financial interests or personal relationship that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF